Genetic - Dr. Pascal Mensah | Ymmunoledge

Why We Can Trust GENOWME

Pascal MENSAH — Tue, 05 May 2026 09:18:32 +0000

Five arguments for trust in epigenetic testing — and the honest counterweight a careful clinician should carry alongside them

GENOWME (Genknowme SA, Lausanne) markets a Swiss epigenetic age and stress-load assay aimed at preventive medicine. Below are five reasons the test deserves clinical credibility, drawn from the company’s own technical documentation and cross-checked against the broader epigenetics literature. The honest counterweight at the end is not a disclaimer — it is the part of the argument that protects the rest from System 1 enthusiasm.

1. Methodological alignment with the field’s gold standard

Genknowme uses the Illumina Infinium MethylationEPIC array on whole-blood DNA after sodium-bisulfite conversion — the same platform behind virtually every major epigenetic clock of the last decade: Horvath, PhenoAge, GrimAge, DunedinPACE, and the methylation analyses in DIRECT-PLUS, DAMA, the Dunedin study, Generation Scotland, and Framingham. The chemistry is shared with academic labs worldwide: bisulfite converts unmethylated cytosines to uracil, leaving methylated cytosines intact, and the array hybridizes the converted DNA to roughly 850,000 CpG-targeted probes for fluorescent readout. This is not a proprietary black box. Whatever Genknowme measures can in principle be re-analyzed and cross- validated against the published literature.

2. Peer-reviewed validation of their proprietary signatures

Their allostatic-load signature is not asserted — it is published. Chamberlain et al. (2025), Bioscience Reports, “Development and validation of an epigenetic signature of allostatic load,” used a two-step process with replication in two independent research cohorts. Their lifestyle methylation signatures for tobacco and alcohol (Chamberlain et al., 2022, Clinical Epigenetics) and their COVID-severity work (2023, Swiss Medical Weekly) are also peer-reviewed. Peer review is not a guarantee of truth, but it is the threshold that separates “we believe” from “external reviewers have scrutinized the model and the data.”

3. Academic provenance and Swiss regulatory oversight

Genknowme is a spin-off of the University of Lausanne and Unisanté, founded by a physician and biologists. Their quality management system is authorized by the Swiss Federal Office of Public Health (OFSP/FOPH), meaning external regulatory inspection of every step in the workflow — extraction, bisulfite conversion, hybridization, scanning, and bioinformatics. This sits inside the Swiss data-protection regime, which guarantees anonymized sample handling and full patient ownership of DNA and results. Most direct-to-consumer “longevity” tests sold in less-regulated markets — particularly in the U.S. wellness space — do not have this governance layer. Regulation is not a substitute for science, but it raises the floor on operational reliability.

4. Population-specific calibration with conditional regression

The “horloge suisse” is calibrated on a Swiss reference population — the country with the highest life expectancy in Europe — using a conditional regression framework that explicitly incorporates lifestyle covariates (diet, alcohol, tobacco, physical activity). This is methodologically distinct from first-generation clocks (Horvath 2013) that were trained on pooled, lifestyle-blind cohorts. Conditioning on lifestyle is exactly what mathematically enables their sensitivity analysis: the ability to compare your declared exposure against the biological signature actually present in your DNA, and flag the discrepancy. That feature — telling whether reported lifestyle and biological reality match — only works if the clock is built this way. It also protects against the well-known weakness of first-generation clocks, which can be confounded by population structure when applied outside their training distribution.

5. Transparency of the gene panel and workflow

Genknowme publishes, in its patient-facing reports, the actual genes it reads. The 11 BioAge markers include ELOVL2, KLF14, AHRR, SLC7A11, FOXK1, JDP2, KCNQ4, PTPRN, IPO8, CALHM2, GPR62 and others — each with hundreds to thousands of aging- or lifestyle-related citations in the literature (ELOVL2 alone is one of the most-validated single-CpG age markers ever described). The 32 allostatic-load CpGs are also disclosed, distributed across the four physiological systems they claim to measure (metabolic, immune, cardiovascular, neuroendocrine). Their workflow is documented at the level of a four-day, roughly seventy-seven-step manual protocol with duplicate runs and a ten-step bioinformatics pipeline, processed in-house in Switzerland. Each marker can be cross-referenced against the literature. Many “biological age” services on the market do not disclose this much.

Trustworthy science is not science that asks to be believed. It is science that publishes its panel, opens its workflow, submits to regulation, and accepts that someone else can audit the result.

The honest counterweight

Five arguments for trust become more — not less — credible when paired with a clear-eyed view of where the trust limit lies. Three caveats are worth carrying alongside the case above:

Technical variance is real. Like every methylation-based clock, the absolute biological-age value is sensitive to white-blood-cell composition, sample handling, and batch effects. A test–retest difference of ±1 to 2 years can occur from technical noise alone. Single-point deltas should not be over-interpreted; longitudinal trends matter more than absolute numbers.
Independent prospective validation is more limited than for the reference clocks. GrimAge and DunedinPACE have decade-long follow-up cohorts (Generation Scotland, Dunedin, Framingham, Lothian Birth Cohorts) demonstrating prediction of mortality, T2D, CVD, dementia, and frailty. The Swiss clock’s predictive performance for these hard endpoints, in Genknowme’s own hands, is not yet published at the same scale. The technical foundation is sound, but the long-tail outcome data is still being built.
A sound test is not automatically a useful clinical decision. Methodological rigor at the laboratory bench does not, by itself, translate into better patient outcomes. The clinical value of an epigenetic- age measurement still depends on the physician’s framework — how the result is communicated, which interventions follow, and whether the patient is re-tested longitudinally to verify response. The test is a tool; the interpretation is medicine.

Read together, these caveats do not weaken the case for GENOWME — they sharpen it. They define what we can responsibly claim with a Swiss epigenetic clock today: a methodologically sound, regulatorily supervised, peer-reviewed-anchored, transparently constructed assay that is best used as part of a longitudinal preventive workflow under physician interpretation, with appropriate humility about absolute numbers.

Trust the method, calibrate the expectation, verify with re-measurement.

Selected references

Chamberlain JD et al. Development and validation of an epigenetic signature of allostatic load. Bioscience Reports. 2025.

Chamberlain JD et al. Blood DNA methylation signatures of lifestyle exposures: tobacco and alcohol consumption. Clinical Epigenetics. 2022.

Chamberlain JD et al. Epigenetic age and COVID-19 severity. Swiss Medical Weekly. 2023.

Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics. 2018;19:371–384.

Lu AT et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11:303–327.

Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.

Hillary RF et al. Epigenetic measures of ageing predict prevalence and incidence of leading causes of death and disease burden. Clinical Epigenetics. 2020;12:115.

Teschendorff AE et al. Epigenetic ageing clocks: statistical methods and emerging computational challenges. Nature Reviews Genetics. 2025.

McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Annals NY Acad Sci. 1998;840:33–44.

Emery O et al. Modifications épigénétiques et maladies cardiovasculaires : nouvel Eldorado. Revue Médicale Suisse. 2024.

The post Why We Can Trust GENOWME first appeared on Dr. Pascal Mensah | Ymmunoledge.

Your DNA Isn’t Your Destiny — Your Daily Choices Are

Pascal MENSAH — Tue, 05 May 2026 08:57:59 +0000

A rational case for understanding the epigenetic clock and its role in healthspan

You inherited your genes. You did not inherit your future. The same DNA you carry from birth to old age is read very differently depending on how you live. That reading layer — the chemical script that decides which genes are switched on or off — is called your epigenome. It is rewritten every day by what you eat, how you move, how you sleep, how you handle stress, and what you breathe. That is why identical twins, who share exactly the same genome, often age very differently. Same code; different choices; different biology.

A measurable trace of how you live

Modern science can now read this layer. By measuring tiny chemical marks (methylation) on your DNA, we estimate your biological age — how old your body actually behaves, regardless of the date on your passport. Hundreds of studies show that biological age predicts your future risk of heart disease, type 2 diabetes, cognitive decline and frailty more accurately than chronological age. It is, in effect, a forward-looking dashboard of your healthspan. GENOWME’s Swiss epigenetic clock measures eleven such markers, calibrated on the population with the highest life expectancy in Europe, plus a stress signature across your metabolic, immune, cardiovascular and neuroendocrine systems — capturing the cumulative wear of chronic stress.

Five levers that move the clock

Across randomized trials, the most effective interventions are also the most accessible:

Eat for your methylation. Mediterranean and plant-rich patterns; polyphenols (green tea, olive oil, berries); folate, B12, choline, omega-3 fatty acids; minimal ultra-processed food.
Move daily. Combined aerobic and strength training; reduce sedentary time. Even short walks lower epigenetic age acceleration.
Protect your sleep. Seven to nine hours, consistent timing, morning light exposure, no late-night meals.
Regulate stress. Meditation, breathwork, social connection. Chronic stress is biologically expensive — your epigenome records every bit of it.
Avoid the obvious toxins. Tobacco, excess alcohol, polluted air. Their epigenetic signatures are unmistakable, and so is their reversal once exposure stops.

Why this changes preventive care

Conventional medicine waits for symptoms. By the time blood pressure, blood sugar or cholesterol cross the line, your biology has been drifting for ten to twenty years. Epigenetic measurement detects that drift early — and, crucially, it can be re- measured. After three to twelve months of a targeted lifestyle protocol, you can see whether your biology actually moved. “I should eat better and exercise more” becomes “my biology shifted from fifty-two to forty-nine — and here is what worked.”

An honest word

The epigenetic clock is not a crystal ball. It is a high-resolution mirror. Lifestyle interventions typically slow aging or shift it back by one to three years; they do not rejuvenate you to a younger self. Different clocks measure different things, and small changes between measurements should not be over-interpreted. But across dozens of randomized trials, the direction is consistent: structured nutrition, movement, sleep and stress regulation move the clock the right way.

Your genes are the score. Your daily choices conduct the performance. The fixed code of your DNA was given to you — the way it is read is a daily decision, written one methyl group at a time.

GENOWME — Genknowme SA, Lausanne · Patient briefing · Sources: Horvath 2018, Belsky 2022 (DunedinPACE), Lu 2019 (GrimAge), Fitzgerald 2021, Yaskolka Meir 2023 (DIRECT-PLUS), Olaso-Gonzalez 2026.

The post Your DNA Isn’t Your Destiny — Your Daily Choices Are first appeared on Dr. Pascal Mensah | Ymmunoledge.

Epigenetics as a Preventive Tool for a Better Healthspan

Pascal MENSAH — Tue, 05 May 2026 08:37:15 +0000

A rational case for understanding epigenetic aging — for educated readers who want to understand, not be sold

Your DNA is not your destiny. Every cell in your body carries the same genome from birth to old age — about three billion base pairs, inherited at conception, that change very little over the course of your life. Yet identical twins, who share that genome, often diverge dramatically in how they age. One develops type 2 diabetes at fifty-five; the other runs marathons at seventy. The genetic code is identical. What differs is the way it is read.

That reading layer is the epigenome: a thin chemical script written on top of DNA that decides which genes are switched on, when, where, and how loudly. Food, exercise, sleep, sunlight, alcohol, tobacco, stress, pollution, social connection — all of these leave biochemical marks on your DNA. Those marks regulate inflammation, metabolism, immune function, and cellular repair. Over years, they accumulate into what we now call your biological age.

The fixed genome is read through a dynamic, modifiable layer — and that layer is open to intervention.

This is the central insight that makes epigenetics the most actionable tool in preventive medicine today: what you cannot change (your genes), the epigenome translates; what you can change (your lifestyle), the epigenome records and propagates. The aim of this paper is to lay out — without hype, and without minimizing what we genuinely know — the rational case for treating epigenetic measurement as a cornerstone of healthspan-oriented care.

1. The core biological principle

Genes provide the score; the epigenome conducts the performance. The genome is essentially fixed at conception. The epigenome is rewritten continuously, throughout life, by your environment and your choices. A useful image is the caterpillar and the butterfly: same DNA, two completely different organisms, because different gene programs are switched on at different stages. In humans, the same principle applies on a slower timescale. The genes you carry at twenty are the genes you carry at seventy; their expression patterns, however, will have shifted thousands of times in response to what you ate, how you slept, how you moved, whom you loved, and what you breathed.

This implies a re-framing of disease. With the exception of true monogenic disorders, most chronic diseases — cardiovascular disease, type 2 diabetes, neurodegeneration, many cancers — are not primarily genetic in origin. They are epigenetic and metabolic. Their roots lie in decades of accumulated cellular wear, written in methylation patterns and chromatin states long before any symptom appears. If we can read that wear, we can act on it before it becomes pathology.

2. Molecular mechanisms — how the epigenome writes, reads, and erases

Four mechanisms do the bulk of the epigenetic work:

DNA methylation. A methyl group (–CH3) is added to specific cytosine bases — mostly at sites called CpG dinucleotides — by enzymes called DNA methyltransferases (DNMTs), and removed by ten- eleven translocation (TET) enzymes. Methylation in a gene’s promoter typically silences the gene; loss of methylation reactivates it. The methyl groups themselves come from S-adenosylmethionine (SAM), which depends on B vitamins (folate B9, B12, B6), choline, and one-carbon metabolism. Your diet directly fuels — or starves — your methylation machinery.
Histone modifications. DNA is wrapped around protein spools called histones. Tags on histone tails — acetylation, methylation, phosphorylation — open or close chromatin, making genes accessible or hidden. The substrates again come from metabolism: acetyl-CoA from glucose and fatty-acid oxidation drives histone acetylation; α-ketoglutarate from the TCA cycle fuels histone demethylases.
The NAD+ / sirtuin axis. Sirtuins (SIRT1–7) are NAD+-dependent deacetylases. They erase acetyl marks on histones and other proteins, and they sit at the centre of mitochondrial biogenesis, DNA repair, circadian regulation, and stress response. NAD+ levels fall with age — by some estimates roughly half between forty and sixty — directly limiting sirtuin activity and accelerating epigenetic drift.
Non-coding RNAs. MicroRNAs and long non-coding RNAs add a fine-tuning layer on top of the others, modulating gene expression in response to environmental cues.

The epigenome is not abstract software. It is a chemical record written by metabolic substrates produced by your mitochondria.

SAM, acetyl-CoA, NAD+, α-ketoglutarate — these are the molecular currencies that translate lifestyle into gene expression. This is exactly why GENOWME’s gene panel makes biological sense. Markers like ELOVL2 (fatty-acid elongation, a canonical aging clock CpG), AHRR (xenobiotic response, a tobacco/pollution sentinel), KLF14 (metabolic regulation), JDP2 (transcriptional stress response), SLC7A11 (redox homeostasis), and FOXK1 (muscle development and repair) sit at the intersection of metabolism, immunity, and cellular stress — exactly where lifestyle leaves its strongest epigenetic footprints.

3. Systems-level interpretation — the epigenetic clock as an integrator

In the 2010s, Steve Horvath and others discovered that DNA methylation patterns at a few hundred CpG sites predict chronological age with extraordinary precision — typically within two to three years. These predictors became known as epigenetic clocks. A second generation (PhenoAge, GrimAge) and a third generation (DunedinPACE) moved beyond chronology: they predict mortality, cardiovascular disease, cancer, frailty, cognitive decline, and the onset of age-related disease — often outperforming traditional clinical risk factors.

These clocks are not magic. They integrate the cumulative biological footprint of several long-running processes: chronic low-grade inflammation (inflammaging), the gradual decline of immune competence (immunosenescence), mitochondrial dysfunction, circadian disruption, and the cumulative wear of chronic stress — what Bruce McEwen called allostatic load. GENOWME’s stress profile measures exactly this allostatic load with thirty-two DNA-methylation markers spread across four physiological systems: metabolic, immune, cardiovascular, and neuroendocrine.

The epigenetic clock is, in this sense, a molecular dashboard of your biology — a single readout that compresses thousands of subclinical processes into one number. A fifty-year-old with a biological age of forty-two is not just aging gracefully; she is, statistically, less likely to develop type 2 diabetes, hypertension, dementia, or coronary heart disease over the next decade than a peer with a biological age of fifty-eight. That is what makes the clock different from any classical biomarker: it is a forward-looking integrator, not a backward-looking symptom.

GENOWME’s specific contribution — the so-called “horloge suisse” (Swiss clock) calibrated on a Swiss reference population (the country with the highest life expectancy in Europe) — adds two practical layers. First, eleven epigenetic biomarkers selected for their lifestyle sensitivity. Second, a sensitivity analysis that compares your declared lifestyle (vegetables, activity, alcohol, tobacco) against the biological signature actually present in your DNA. That comparison is where the clinical insight lives.

4. A quantitative and thermodynamic perspective

A useful way to think about aging is in terms of information and entropy. The epigenome is, in part, an information storage system — methylation and chromatin patterns that tell each cell what to do. Over time, those patterns degrade. Methylation entropy increases: sites that should be tightly methylated drift toward partial methylation; sites that should be unmethylated drift the other way. The signal becomes noisier; the cell’s instructions become less clear.

Maintaining low-entropy epigenetic patterns is not free. Every methyl group transferred by a DNMT consumes one SAM (regenerated through ATP-dependent one-carbon metabolism). Every histone deacetylation by a sirtuin consumes one NAD+. Every chromatin remodeling event consumes ATP.
Maintaining youthful gene expression is, fundamentally, a thermodynamic battle against entropy — and that battle is fought by your mitochondria.

This explains a deep symmetry in the data. Mitochondrial dysfunction lowers NAD+ and acetyl-CoA → impairs sirtuin and chromatin function → drives epigenetic drift → accelerates biological aging. Conversely, caloric restriction, time-restricted eating, structured exercise, and quality sleep boost mitochondrial function → restore NAD+ → reactivate sirtuins → slow epigenetic aging. The same axis works in both directions, and the clock is sensitive enough to detect the swing.

The quantitative evidence has accumulated quickly:

An eight-week diet-and-lifestyle intervention reduced Horvath DNAmAge by approximately 3.2 years versus controls (Fitzgerald et al., 2021).
A twenty-four-month diet and physical-activity trial in postmenopausal women slowed GrimAge progression and reduced stochastic epigenetic mutations in cancer-related pathways (Fiorito et al., 2021, DAMA study).
An eighteen-month polyphenol-rich Mediterranean (“Green-MED”) diet attenuated multiple epigenetic clocks; participants showed roughly 8.9 months of favorable difference in biological age (Yaskolka Meir et al., 2023, DIRECT-PLUS).
A six-month multidomain intervention (nutrition + supervised exercise) in frail elders reduced PhenoAge and preserved methylation-based telomere length (Olaso-Gonzalez et al., 2026).
A very-low-calorie ketogenic diet decelerated biological age in obese patients across three independent clocks (Izquierdo et al., 2025).
Each one-standard-deviation increase in DunedinPACE predicts roughly 16% higher hypertension incidence (Kresovich et al., 2023) and 27% higher dementia risk (Belsky et al., 2022).
GrimAge predicts time-to-death, time-to-coronary heart disease, and time-to-cancer with effect sizes comparable to or stronger than classical risk factors (Lu et al., 2019; Hillary et al., 2020).

These numbers matter because they are not only associations. Several are randomized controlled trials, demonstrating bidirectional plasticity: the clock can speed up under stress and slow down under intervention, within months. That is the property that turns a biomarker into a clinical tool.

5. Clinical and translational implications

For preventive medicine, this changes the practice in three concrete ways.

5.1 — From symptoms to subclinical biology

Conventional medicine is reactive: it intervenes when symptoms or lab values cross a threshold (HbA1c above 6.5%, LDL above 190 mg/dL, blood pressure above 140/90). By that point the underlying biology has been deteriorating for ten to twenty years. Epigenetic aging measures detect that deterioration before any classical threshold is crossed. They move the diagnostic window upstream — from disease to biological readiness for disease.

5.2 — From population recommendations to personalized lifestyle dose-response

Public-health guidelines are uniform: five portions of vegetables a day, 150 minutes of activity a week, no more than two standard drinks. But people respond to those inputs very differently, and uniform advice cannot tell who is responding well. GENOWME’s sensitivity analysis captures exactly this. Someone who reports drinking three drinks a week but shows the methylation signature of seven is metabolically vulnerable and needs a tighter intervention. Someone who reports moderate exercise but shows the signature of an athlete is biologically protected. The same lifestyle input yields different epigenetic outputs — and only the epigenome reveals it.

5.3 — From single biomarkers to a longitudinal tracker

Because epigenetic patterns shift within weeks to months, the clock can be re-measured to monitor whether an intervention is working. This converts vague advice (“you should eat better”) into closed-loop biofeedback: did the last six months actually move your biology? For the patient, that is the difference between abstract guidance and a verifiable result. For the clinician, it is the difference between hope and evidence.

5.4 — The lifestyle levers that move the clock

The interventions with the strongest evidence for slowing epigenetic aging are, reassuringly, the ones with strong evidence for everything else:

Nutrition. Mediterranean and plant-rich patterns; polyphenols (green tea, olive oil, berries, herbs); adequate folate, B12, B6, and choline (the substrates of methylation); omega-3 fatty acids; minimal ultra-processed food and added sugar.
Movement. Combined aerobic and resistance training; reduction of sedentary time; even short bouts of light activity reduce epigenetic age acceleration.
Sleep and circadian alignment. Seven to nine hours, consistent timing, morning light exposure, restricted late-night eating. Circadian disruption shows up in epigenetic clocks within weeks.
Stress regulation. Meditation, breathwork, social connection, time in nature — strategies that reduce chronic allostatic load, which is exactly the variable GENOWME’s stress profile measures across metabolic, immune, cardiovascular, and neuroendocrine systems.
Avoidance of toxic exposures. Tobacco, excess alcohol, air pollution. The epigenetic signatures of these exposures are unambiguous and well validated.
Targeted micronutrients. Folate, B12, choline, magnesium, vitamin D — the substrates of methylation and chromatin chemistry. Deficiencies are common and easily corrected.

For a clinic, this defines a clean preventive workflow: measure epigenetic age and stress signature → map the lifestyle inputs → intervene for three to twelve months → re-measure → iterate. This is the operational meaning of “precision preventive medicine”.

6. A cognitive-bias check — what not to overclaim

Daniel Kahneman’s distinction between System 1 (fast, intuitive, emotionally compelling) and System 2 (slow, analytical, evidence-weighted) is worth applying to ourselves before we apply it to patients. The longevity field is uniquely vulnerable to System 1 reasoning: “biological age” sounds magical, photogenic, and instantly meaningful — it activates hope, vanity, and fear all at once, which is exactly the configuration
that produces bad decisions and bad science. So a few honest caveats:

Different clocks measure different things. Horvath’s first-generation clock tracks chronological age; GrimAge tracks mortality; DunedinPACE tracks pace of aging. They overlap but do not agree perfectly, and they capture related but distinct biology.
Reversibility has limits. Most lifestyle interventions slow the rate of aging or shift it back by one to three years; they do not “rejuvenate” you to a younger self. Cellular reprogramming is a research frontier, not a clinical reality.
Measurement variance matters. A clock value can shift by one to two years between measurements just from technical noise, blood-cell composition, or recent illness. Small changes should not be over-interpreted.
Causality is partial. Clocks correlate strongly with disease risk; they do not prove site-by-site causation. New causality-enriched clocks (DamAge, AdaptAge) are beginning to address this (Ying et al., 2023).
Lifestyle remains the lever. No supplement, peptide, or pharmacological “anti-aging” intervention has yet outperformed a structured combination of nutrition, exercise, sleep, and stress regulation in randomized trials.

The epigenetic clock is the best integrative biomarker we have for preventive medicine, and it is good enough to act on — provided we measure carefully, intervene with evidence, and track outcomes longitudinally. It is not a crystal ball. It is a high-resolution mirror.

7. Why this matters now

For most of the twentieth century, medicine waited for disease. The twenty-first century has the tools to act before disease. Genetics tells you your predispositions; the epigenome tells you how you are using them — and how to redirect them.

By measuring your epigenetic age and your stress signature today, then again in six months after a targeted lifestyle protocol, you convert “I should eat better and exercise more” into “my biology shifted from fifty-two to forty-nine — and here is what worked.” That is the closest thing modern medicine has to a longitudinal, modifiable, scientifically validated dashboard of your healthspan.

That is the rational case for placing epigenetic measurement at the centre of preventive care. It is mechanistically grounded. It is quantitatively measurable. It is biologically modifiable. It is clinically actionable. And, applied with discipline, it is honest about its limits.

The fixed code of your DNA was given to you. The way it is read is a daily decision — written one methyl group at a time.

Selected references

Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics. 2018;19:371–384.

Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303–327.

Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.

Fitzgerald KN, Hodges R, Hanes D, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging (Albany NY). 2021;13(7):9419–9432. Correction 2024.

Fiorito G, Caini S, Palli D, et al. DNA methylation-based biomarkers of aging were slowed down in a two-year diet and physical activity intervention trial: the DAMA study. Aging Cell. 2021;20(10):e13439.

Yaskolka Meir A, Keller M, Hoffmann A, et al. The effect of polyphenols on DNA methylation-assessed biological age attenuation: the DIRECT-PLUS randomized controlled trial. BMC Medicine. 2023;21:364.

Olaso-Gonzalez G, et al. A multidomain lifestyle intervention is associated with improved functional trajectories and favorable changes in epigenetic aging markers in frail older adults: a randomized controlled trial. Aging Cell. 2026.

Izquierdo AG, Crujeiras AB, et al. Epigenetic aging acceleration in obesity is slowed down by nutritional ketosis following very- low-calorie ketogenic diet (VLCKD). Nutrients. 2025.

Hillary RF, McCartney DL, Bermingham ML, et al. Epigenetic measures of ageing predict the prevalence and incidence of leading causes of death and disease burden. Clinical Epigenetics. 2020;12:115.

Kresovich JK, Park YM, Keller JA, et al. Methylation-based biological age and hypertension prevalence and incidence. Hypertension. 2023.

McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Annals of the New York Academy of Sciences. 1998;840:33–44.

Chamberlain JD, et al. Development and validation of an epigenetic signature of allostatic load. Bioscience Reports. 2025.

Galkin F, Kovalchuk O, Koldasbayeva D, Zhavoronkov A, Bischof E. Stress, diet, exercise: common environmental factors and their impact on epigenetic age. Ageing Research Reviews. 2023.

Pereira B, Correia FP, Alves IA, et al. Epigenetic reprogramming as a key to reverse ageing and increase longevity. Ageing Research Reviews. 2024.

Ying K, Liu H, Tarkhov AE, et al. Causality-enriched epigenetic age uncouples damage and adaptation. bioRxiv / Nature Aging. 2023.

Yamada H. Epigenetic clocks and EpiScore for preventive medicine: risk stratification and intervention models for age-related diseases. Journal of Clinical Medicine. 2025.

Topart C, Werner E, Arimondo PB. Wandering along the epigenetic timeline. Clinical Epigenetics. 2020;12:97.

Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019;18(6):e13028.

Kahneman D. Thinking, Fast and Slow. New York: Farrar, Straus and Giroux; 2011.

Drafted with reference to GENOWME (Genknowme SA, Lausanne) sample reports — BioAge & Lifestyle and Stress Overload — and to peer-reviewed primary literature retrieved via Consensus / Semantic Scholar in May 2026. The biological claims are sourced from randomized trials and reviews; the cognitive-bias caveats are the author’s own.

The post Epigenetics as a Preventive Tool for a Better Healthspan first appeared on Dr. Pascal Mensah | Ymmunoledge.